Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide maintenance after R-CHOP in elderly patients with diffuse large B-cell lymphoma
ACTRN12611000085976Phase 3Active, not recruiting
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Australasian Leukaemia & Lymphoma Group. Primary endpoint: Progression-free survival. Started Mar 2011; status: active, not recruiting.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ACTRN12611000085976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000085976.